Vol. 5 No. 10 (2025)
Reimbursement Recommendations

Nivolumab Plus Ipilimumab (Opdivo Plus Yervoy)

decorative image of the issue cover

Published October 22, 2025

Key Messages

  • Canada’s Drug Agency (CDA-AMC) recommends that Opdivo in combination with Yervoy be reimbursed by public drug plans for the first-line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer, if certain conditions are met.
  • Opdivo in combination with Yervoy should only be covered to treat adult patients with histologically confirmed, locally advanced, unresectable or metastatic colorectal cancer (mCRC)that has not previously been treated with systemic therapy for advanced disease and is not amenable to surgery and that has a known tumour MSI-H or dMMR status based on validated test(s) per local standard of practice.
  • Opdivo in combination with Yervoy should only be reimbursed if prescribed by clinicians with expertise in the diagnosis and treatment of patients with mCRC and if the cost of Opdivo in combination with Yervoy is reduced.